SecBot SecBot
8-K ·Filed Jun 22, 2026

CTMX

CytomX Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001193125-26-277631
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

These are standard post-annual-meeting governance filings with no immediate trading catalyst. The authorized share increase provides headroom for potential future capital raises or M&A but carries no current dilution. Monitor future filings for actual equity grants or any capital markets activity that would utilize the new share authorization.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.15
T+0 close · Jun 22, 2026 · via day close
Latest settled
−12.22%
T+60 · $2.77
Vs SPY
−15.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $3.15entry
  2. T+1 · 5mo ago +5.40%α +5.44% · $3.32
  3. T+5 · 5mo ago +18.73%α +17.72% · $3.74
  4. T+20 · 4mo ago +11.75%α +10.59% · $3.52
  5. T+60 · 2mo ago −12.22%α −15.47% · $2.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockholders approved a charter amendment to double authorized common shares from 300M to 600M, an amendment to the 2015 Equity Incentive Plan adding 6.5M new shares, and an amendment to the Employee Stock Purchase Plan adding 1M shares. These are routine governance and equity plan replenishments that enable future compensation grants and capital flexibility but signal no immediate operational change.

Key Facts

  • Stockholders approved an amendment to the certificate of incorporation increasing authorized common shares from 300,000,000 to 600,000,000.
  • Stockholders approved an amendment to the 2015 Equity Incentive Plan, increasing shares authorized for issuance by 6,500,000 shares.
  • Stockholders approved an amendment to the Employee Stock Purchase Plan, increasing shares authorized for issuance by 1,000,000 shares.
  • All seven proposals at the Annual Meeting were approved by stockholders; there were no contested matters or director departures.

Financial Impact

No immediate financial impact. The authorized share increase and equity plan amendments are routine enabling actions that do not trigger any cash transaction or change in reported financials.

Risk Factors

  • Potential future dilution if the newly authorized shares are issued in a secondary offering or equity compensation. The share count increase from 300M to 600M authorized gives the company significant capacity for future dilution without further stockholder approval.
  • The charter amendment and equity plan increases may precede future capital raises, which could pressure the stock price if executed at a discount.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-277631
Document: d154321d8k.htm0001193125-26-277631
Document: d154321dex102.htm0001193125-26-277631
Document: d154321dex31.htm0001193125-26-277631
Document: 0001193125-26-277631-index-headers.html0001193125-26-277631
Document: 0001193125-26-277631-index.html0001193125-26-277631
Document: 0001193125-26-277631.txt0001193125-26-277631

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026